 EDIT stock has been on a roller coaster this year, but it may be at an appealing price for speculative buyers who believe in its CRISPR tech. The post Editas Medicine Could Skyrocket if Its Gene Editing Therapy Proves Successful appeared first on InvestorPlace. 